Keyphrases
Ketamine
100%
Treatment-resistant Depression
78%
Depression Treatment
25%
Ketamine Treatment
24%
Major Depressive Disorder
23%
Patient Experience
22%
Depression Severity
22%
Antidepressants
20%
Electroconvulsive Therapy
17%
Depressive Symptoms
16%
Psilocybin
14%
PubMed
14%
Treatment-resistant
13%
Adverse Events
13%
Netherlands
13%
Monoamine Oxidase Inhibitors
12%
Interpretative Phenomenological Analysis
12%
Pharmacodynamic Interactions
11%
Anxiety Symptoms
11%
Operant Behavior
11%
History of Psychosis
11%
Treatment for Depression
11%
Sleep Restriction
11%
Comorbidity
11%
Clinical Forensics
11%
Psychiatric Medication
11%
Deep Sleep
11%
Deep Brain Stimulation
11%
Prefrontal Cortex
11%
Psychotic Symptoms
11%
Mixed Methods Evaluation
11%
Randomized Placebo-controlled Trial
11%
Serum Biomarkers
11%
Phenomenology
11%
Letting Go
11%
Clinical Treatment
11%
Insomnia Disorder
11%
Open-label Extension
11%
Pathophysiology
11%
Insomnia
11%
Therapeutic Potential
11%
Phenomenological Study
11%
Intranasal Ketamine
11%
Changes with Age
11%
Systematic Literature Review
11%
Serotonergic Psychedelics
11%
Urinary Biomarkers
11%
Treatment Response
11%
Response Predictors
11%
Embase
9%
Neuroscience
Treatment-Resistant Depression
47%
Esketamine
45%
Ketamine
44%
Sleep Disorder
39%
Sleep Quality
32%
Behavior (Neuroscience)
28%
Antidepressant
28%
Treatment of Depression
23%
Placebo
22%
Depression
20%
Hostility
19%
Mental Disorder
18%
Hypothalamic-Pituitary-Adrenal Axis
17%
Prefrontal Cortex
17%
Anxiety Disorder
15%
Non-Rapid Eye Movement Sleep
12%
Rapid Eye Movement Sleep
12%
Major Depressive Disorder
12%
Cognitive Function
11%
Quetiapine
11%
Mirtazapine
11%
Electroconvulsive Therapy
11%
Serotonin
11%
Encephalopathy
11%
Locus Coeruleus
11%
Tau Protein
11%
Beta Amyloid
11%
Aggression
8%
Randomized Controlled Trial
8%
Brain Areas
5%
Electroencephalography
5%
Sleep Pattern
5%
Problem Behavior
5%
Serotonergic
5%
Sleep Time
5%
Pharmacology, Toxicology and Pharmaceutical Science
Treatment Resistant Depression
57%
Ketamine
53%
Esketamine
48%
Antidepressant
36%
Randomized Controlled Trial
27%
Symptom
25%
Adverse Event
19%
Tolerability
17%
Placebo
15%
Psychotomimetic
14%
Psilocybin
13%
Pharmacodynamics
12%
Monoamine Oxidase Inhibitor
12%
Major Depression
12%
Remission
6%
Side Effect
5%
